Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17885856 | 0.87 | ALDH1A1 (0.68) | ALDH1A1CREBBPKAT2BSMN1; SMN2CNR2 | |
| SCHEMBL28589803 | 0.85 | SLC22A12 (0.61) | PLK1CREBBPKMT2AMEN1CNR2 | |
| SCHEMBL5069182 | 0.85 | PLK1 (0.64) | PLK1ALDH1A1MAPTCREBBPKMT2A | |
| SCHEMBL1127864 | 0.85 | NR4A2 (0.68) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5065671 | 0.83 | CNR2 (0.68) | PLK1ALDH1A1MAPTCREBBPCNR2 | |
| SCHEMBL28577087 | 0.82 | CNR2 (0.53) | ALDH1A1MAPTCREBBPKMT2AMEN1 | |
| SCHEMBL12168491 | 0.81 | CNR2 (0.65) | PLK1ALDH1A1MAPTCREBBPKMT2A | |
| SCHEMBL30384771 | 0.81 | CNR2 (0.65) | PLK1ALDH1A1MAPTCREBBPKMT2A | |
| SCHEMBL2643935 | 0.81 | PTGDR2 (0.43) | PLK1ALDH1A1MAPTKMT2ACNR2 | |
| SCHEMBL13619970 | 0.81 | KMT2A (0.44) | ALDH1A1KMT2AMEN1CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651922-A1 | INDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | Janssen R&D Ireland (IE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080447-A1 | INDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
| CN-102026990-A | Novel inhibitors of hepatitis c virus replication | INTERMUNE INC | 2011-04-20 | — | — | CN | disclosed |
| EP-2283002-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009134616-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134616-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HDGF | PLK1 1054/4885ALDH1A1 1614/4885MAPT 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.